Prevention and Management of Recurrent Disease after Arterial Reconstruction: New Prospects for Pharmacological Control

• References

• 1 Szilagyi DE, Elliott JP, Hageman JH, Smith RF. Dall'olmo Biologic fate of autogenous vein implants as arterial substitutes. Ann Surg 1973; 178: 232-245
• 2 Sladen JG, Gilmour JL. Vein graft stenosis. Characteristics and effect of treatment. Am J Surg 1981; 141: 549-553
• 3 Whittemore AD, Clowes AW, Couch NP, Mannick JA. Secondary femoropopliteal reconstruction. Ann Surg 1981; 193: 35-42
• 4 Bandyk DF, Schmitt DD, Seabrook GR, Adams MB, Towne JB. Monitoring functional patency of in situ saphenous vein bypasses: The impact of a surveillance protocol and elective revision. J Vasc Surg 1989; 9: 286-296
• 5 Healy DA, Clowes AW, Zierler RE, Nicholls SC, Bergelin RO, Primozich JF, Strandness Jr DE. Immediate and long-term results of carotid endarterectomy. Stroke 1989; 20: 1138-1142
• 6 Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-1387
• 7 Fanelli C, Aronoff R. Restenosis following coronary angioplasty. Am Heart J 1990; 119: 357-368
• 8 Johnston KW, Rae M, Hogg-Johnston SA, Colapinto RF, Walker PM, Baird RJ, Sniderman KW, Kalman P. 5-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 1987; 206: 403-413
• 9 Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients: Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80: 1726-1736
• 10 Baumgartner HR, Studer A. Consequences of vessel catheterization in normal and hypercholesterolemic rabbits. Pathology and Microbiology 1966; 29: 393-405
• 11 Stemerman MB, Ross R. Fibrous plaque formation in primates, an electron microscope study. J Exp Med 1972; 136: 769-789
• 12 Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury.I.Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333
• 13 Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208-215
• 14 Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore S, Mustard JF. Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. Lab Invest 1982; 46: 605-612
• 15 Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987; 61: 296-300
• 16 Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985; 56: 139-145
• 17 Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury. III.Endothelial and smooth muscle growth in chronically denuded vessels. Lab Invest 1986; 54: 295-303
• 18 Reidy MA, Clowes AW, Schwartz SM. Endothelial regeneration. V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 1983; 49: 569-575
• 19 Clowes AW, Kirkman TR, Clowes MM. Mechanisms of arterial graft failure. II. Chronic endothelial and smooth muscle cell proliferation in healing polytetrafluoroethylene prostheses. J Vasc Surg 1986; 3: 877-884
• 20 Berger K, Sauvage LR, Rao AM, Wood SJ. Healing of arterial prostheses in man: its incompleteness. Ann Surg 1972; 175: 118-127
• 21 Clowes AW, Collazzo RE, Karnovsky MJ. A morphologic and permeability study of luminal smooth muscle cells after arterial injury in the rat. Lab Invest 1978; 39: 141-150
• 22 Reidy MA. Endothelial regeneration. VIII. Interaction of smooth muscle cells with endothelial regrowth. Lab Invest 1988; 59: 36-43
• 23 Friedman RJ, Stemerman MB, Wenz B, Moore S, Gauldie J, Gent M, Tiell ML, Spaet TH. The effect of thrombocytopenia on experimental atherosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest 1977; 60: 1191-1201
• 24 Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974; 71: 1207-1210
• 25 Ross R. Pathogenesis of atherosclerosis-an update. N Engl J Med 1986; 314: 488-500
• 26 Bowen-Pope DF, Ross R, Seifert RA. Locally acting growth factors for vascular smooth muscle cells: endogenous synthesis and release from platelets. Circulation 1985; 72: 735-740
• 27 Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989; 86: 8412-8416
• 28 Jawien A, Lindner V, Bowen-Pope DF, Schwartz SM, Reidy MA, Clowes AW. Platelet-derived growth factor (PDGF) stimulates arterial smooth muscle cell proliferation in vivo.. FASEB J 1990; 4: 342 (Abstract)
• 29 Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery.. J Cardiovasc Pharmacol 1989; 14 Suppl. 6 S12-S15
• 30 Lindner V, Reidy MA, Fingerle J. Regrowth of arterial endothelium. Denudation with minimal trauma leads to complete endothelial cell regrowth. Lab Invest 1989; 61: 556-563
• 31 Fingerle J, Au YPT, Clowes AW, Reidy MA. Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 1990; 10: 1082-1087
• 32 Burgess WH, Maciag T. The heparin binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 1989; 58: 575-606
• 33 Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis. Arteriosclerosis 1989; 9: 269-278
• 34 Gajdusek CM, Schwartz SM. Comparison of intracellular and extracellular mitogen activity. J Cell Physiol 1984; 121: 316-322
• 35 McNeil PL, Muthukrishnan L, Warder E, D'Amore PA. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989; 109: 811-822
• 36 Gajdusek CM, Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol 1989; 139: 570-579
• 37 Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990; 85: 2004-2008
• 38 Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106-113
• 39 Majesky MW, Daemen MJAP, Schwartz SM. Alpha₁-Adrenergic stimulation of platelet-derived growth factor A-chain gene expression in rat aorta. J Biol Chem 1990; 265: 1082-1088
• 40 Miano JM, Tota RR, Vlasic N, Danishefsky KJ, Stemerman MB. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol 1990; 137: 761-765
• 41 Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 1990; 66: 1755-1760
• 42 Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990; 111: 2149-2158
• 43 Golden MA, Au YPT, Kirkman TR, Wilcox JN, Raines EW, Ross R, Clowes AW. Platelet derived growth factor activity and mRNA expression in healing vascular grafts in baboons. The association in vivo of PDGF mRNA and protein with cellular proliferation. J Clin Invest 1991 in press
• 44 Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta during repair of arterial injury. J Clin Invest 1991 in press
• 45 Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-188
• 46 Powell JS, Müller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition.. J Cardiovasc Pharmacol 1990; 16 Suppl. 4 S42-S49
• 47 Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. Gamma interferon regulates vascular smooth muscle proliferation and Ia espression in vitro and in vivo. Circ Res 1988; 63: 712-719
• 48 Clowes AW, Clowes MM. Regulation of smooth muscle proliferation by heparin in vitro and in vivo. International Angiology 1987; 6: 45-51
• 49 Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-626
• 50 Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985; 52: 611-616
• 51 Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. IV.Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 1986; 58: 839-845
• 52 Hoover RL, Rosenberg R, Haering W, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res 1980; 47: 578-583
• 53 Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984; 118: 253-256
• 54 Fritze LMS, Reilly CF, Rosenberg RD. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 1985; 100: 1041-1049
• 55 Castellot Jr JJ, Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981; 90: 372-379
• 56 Castellot Jr JJ, Favreau LV, Karnovsky MJ, Rosenberg RD. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem 1982; 257: 11256-11260
• 57 Schmidt A, Buddecke E. Bovine arterial smooth muscle cells synthesize two functionally different proteoheparan sulfate species. Exp Cell Res 1990; 189: 269-275
• 58 Clowes AW. The role of aspirin in enhancing arterial graft patency. J Vasc Surg 1986; 3: 381-385
• 59 Clagett GP, Genton E, Salzman EW. Antithrombotic therapy in peripheral vascular disease. Chest 1989; 95: 128S-139S
• 60 Schwartz L, Lesperance J, Bourassa MG, Eastwood C, Kazim F, Arafah M, Ganassin L. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty. Am Heart J 1990; 119: 232-236
• 61 Goodnight SH, Fisher M, Fitzgerald GA, Levine PH. Assessment of the therapeutic use of dietary fish oil in atherosclerotic vascular disease and thrombosis. Chest 1989; 95: 19S-25S
• 62 Jackson CL, Bush RC, Bowyer DE. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 1989; 80: 17-26
• 63 El-Sanadiki MN, Cross KS, Murray JJ, Schuman RW, Mikat E, McCann RL, Hagen P-O. Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. Ann Surg 1990; 212: 87-96
• 64 Schlant RC, King III SB. Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.. Circulation 1989; 80 Suppl. IV88-IV92
• 65 Sowers JR. Calcium channel blockers and atherosclerosis. Am J Kidney Dis 1990; 16 Suppl. 1 3-9
• 66 Henry PD. Antiatherogenic effects of calcium-channel blockers: Possible mechanisms of action. Cardiovasc Drugs Ther 1990; 4 Suppl. 5 1015-1020
• 67 Johansson SR, Lamm C, Bondjers G, Emanuelsson H, Hjalmarson Å. Role of beta-adrenergic blockers after percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 66: 915-920
• 68 Chervu A, Moore WS, Quinones-Baldrich WJ, Henderson T. Efficacy of corticosteroids in suppression of intimal hyperplasia. J Vasc Surg 1989; 10: 129-134
• 69 Pepine CJ, Hirshfeld JW, Macdonald RG, Henderson MA, Bass TA, Goldberg S, Savage MP, Vetrovec G, Cowley M, Taussig AS, Whitworth HB, Margolis JR, Hill JA, Bove AA, Jugo R. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990; 81: 1753-1761
• 70 Lundergan C, Foegh ML, Vargas R, Eufemio M, Bormes GW, Kot PA, Ramwell PW. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034. Atherosclerosis 1989; 80: 49-55
• 71 Burgess WH, Shaheen AM, Ravera M, Jaye M, Donohue PJ, Winkles JA. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J Cell Biol 1990; 111: 2129-2138
• 72 Fantl WJ, Escobedo JA, Williams LT. Mutations of the platelet-derived growth factor receptor that cause a loss of ligand-induced conformational change, subtle changes in kinase activity, and impaired ability to stimulate DNA synthesis. Mol Cell Biol 1989; 9: 4473-4478
• 73 Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989; 244: 1344-1346
• 74 Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244: 1342-1344
• 75 Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989; 80: 1347-1353
• 76 Snow AD, Bolender RP, Wight TN, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137: 313-330
• 77 Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. I. In vivo studies with anticoagulant and non-anticoagulant heparin. Circ Res 1980; 46: 625-634
• 78 Castellot Jr JJ, Beeler DL, Rosenberg RD, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984; 120: 315-320
• 79 Castellot Jr JJ, Choay J, Lormeau JC, Petitou M, Sache E, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J Cell Biol 1986; 102: 1979-1984
• 80 Flaumenhaft R, Moscatelli D, Rifkin DB. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J Cell Biol 1990; 111: 1651-1659
• 81 Reilly CF, Fritze LMS, Rosenberg RD. Heparin-like molecules regulate the number of epidermal growth factor recptors on vascular smooth muscle cells. J Cell Physiol 1988; 136: 23-32
• 82 Reilly CF, Kindy MS, Brown KE, Rosenberg RD, Sonenshein GE. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem 1989; 264: 6990-6995
• 83 Wright Jr TC, Pukac LA, Castellot Jr JJ, Karnovsky MJ, Levine RA, Kim-Park HY, Campisi J. Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase C-dependent pathway. Proc Natl Acad Sci U S A 1989; 86: 3199-3203
• 84 Pukac LA, Castellot Jr JJ, Wright Jr TC, Caleb BL, Karnovsky MJ. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Reg 1990; 1: 435-443
• 85 Clowes AW, Clowes MM, Au YPT, Kenagy R. Heparin inhibits tissue plasminogen activator expression in injured rat carotid artery.. FASEB J 1990; 4: 480 (Abstract)
• 86 Au YPT, Clowes AW. Effect of heparin on interstitial collagenase and tissue plasminogen activator expression.. J Cell Biol 1990; 111: 234 (Abstract)